Tixagevimab/AZD8895 represents a distinct treatment method utilizing paired monoclonal antibodies. Specifically, these agents operate by selectively attaching to the spike domain of the SARS-CoV-2 pathogen, inhibiting https://dirstop.com/story29560392/tixagevimab-azd8895-a-deep-analysis-into-its-process-of-operation